Literature DB >> 12602534

Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease.

G Aimaretti1, C Baffoni, L Di Vito, S Grottoli, D Gaia, V Gasco, R Giordano, Z Zadik, F Camanni, E Ghigo, E Arvat.   

Abstract

It is widely accepted that the classical dose of 250.0 microg ACTH (1-24) (tetracosactin) is clearly supra-maximal while 1.0 and 0.03 microg have been shown as the maximal and the lowest stimulatory ACTH doses for cortisol (F) secretion in normal young subjects. Testing with low ACTH dose would better evaluate adrenal sensitivity to corticotropin. The aims of the present study were: a) to clarify the adrenal sensitivity to ACTH in patients with different duration of corticotroph insufficiency by testing with low and very low tetracosactin doses; and b) to evaluate diagnostic implication regarding the ability of ACTH tests to distinguish patients with corticotroph insufficiency from normal subjects. In 24 hypopituitaric patients (HYPOPIT, 15 male and 9 female, age 22-50 yr, BMI: 22-26 kg/m2) with corticotrophin deficiency we studied the F, DHEA and aldosterone (A) responses to challenges with low ACTH doses (0.06 or 0.5 microg iv at 0 min) followed by 250 microg iv (at +60 min). The results in HYPOPIT were compared with those recorded in 12 normal controls (NS, 6 male and 6 female, age 22-34 yr, BMI: 20-25 kg/m2). Basal F and DHEA levels in HYPOPIT were lower than in NS, while A levels were similar in both groups. The F responses to ACTH in HYPOPIT were dose-independent and markedly lower (p < 0.0001) than in NS. After the 0.06 and 0.5 microg ACTH dose, 16% of HYPOPIT patients showed AF peak within the range of normal response. No HYPOPIT showed AF peak within the normal range after 250 microg ACTH. The DHEA responses to ACTH in HYPOPIT were dose-independent and markedly lower than in NS (p < 0.0001). Overlap between individual DHEA responses in HYPOPIT and NS was present after 0.06 microg and 0.5 microg but not after 250 microg tetracosactin. The A responses in HYPOPIT were dose-dependent and overlapped with those in NS. The adrenal responses to ACTH in HYPOPIT were not associated with the duration of the disease. In conclusion, the present study shows that the mean F and DHEA but not the A responses to ACTH (1-24) are markedly impaired in hypopituitaric patients with corticotroph insufficiency independently of the duration of the disease. The impaired F and DHEA response to ACTH is also independent of the dose, suggesting the existence of relatively enhanced sensitivity of the fasciculata and reticularis adrenal zone to ACTH but meantime remarkable impairment of the adrenal function due to corticotrophin deficiency. In the present study, testing with submaximal ACTH doses did not distinguish patients with secondary adrenal insufficiency from normal subjects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12602534     DOI: 10.1007/BF03345122

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.

Authors:  W Oelkers; S Diederich; V Bähr
Journal:  J Clin Endocrinol Metab       Date:  1992-07       Impact factor: 5.958

2.  Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease.

Authors:  J Mayenknecht; S Diederich; V Bähr; U Plöckinger; W Oelkers
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

Review 3.  Dose-response aspects in the clinical assessment of the hypothalamo-pituitary-adrenal axis, and the low-dose adrenocorticotropin test.

Authors:  W Oelkers
Journal:  Eur J Endocrinol       Date:  1996-07       Impact factor: 6.664

4.  One microgram is the lowest ACTH dose to cause a maximal cortisol response. There is no diurnal variation of cortisol response to submaximal ACTH stimulation.

Authors:  G Dickstein; D Spigel; E Arad; C Shechner
Journal:  Eur J Endocrinol       Date:  1997-08       Impact factor: 6.664

Review 5.  Dehydroepiandrosterone (DHEA): a fountain of youth?

Authors:  E E Baulieu
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

6.  Adrenal androgen response to metyrapone, adrenocorticotropin, and corticotropin-releasing hormone stimulation in children with hypopituitarism.

Authors:  S Y Pang; A Legido; L S Levine; J W Temeck; M I New
Journal:  J Clin Endocrinol Metab       Date:  1987-08       Impact factor: 5.958

7.  Re-evaluation of the clinical value of the 30 min ACTH test in assessing the hypothalamic-pituitary-adrenocortical function.

Authors:  J Lindholm; H Kehlet
Journal:  Clin Endocrinol (Oxf)       Date:  1987-01       Impact factor: 3.478

8.  Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids.

Authors:  J Broide; R Soferman; S Kivity; A Golander; G Dickstein; Z Spirer; Y Weisman
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

9.  The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary diseases.

Authors:  K Tordjman; A Jaffe; N Grazas; C Apter; N Stern
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

10.  Cortisol, androstenedione (A4), dehydroepiandrosterone sulphate (DHEAS) and 17 hydroxyprogesterone (17OHP) responses to low doses of (1-24)ACTH.

Authors:  N A Bridges; P C Hindmarsh; P J Pringle; J W Honour; C G Brook
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

View more
  2 in total

1.  The diagnosis of secondary adrenal insufficiency: low dose vs high dose ACTH stimulation test.

Authors:  A Colao; R Pivonello
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

2.  Measurements of serum DHEA and DHEA sulphate levels improve the accuracy of the low-dose cosyntropin test in the diagnosis of central adrenal insufficiency.

Authors:  Laure Sayyed Kassem; Katia El Sibai; Joumana Chaiban; Dima Abdelmannan; Baha M Arafah
Journal:  J Clin Endocrinol Metab       Date:  2012-07-31       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.